4D-Nucleofector™ LV Unit
For closed, scalable large-scale transfection of up to 1x109 cells
PRODUCT OVERVIEW: Large-Scale Transfection Using the 4D-NucleofectorTM LV Unit. The LV Unit... more
PRODUCT OVERVIEW:
Large-Scale Transfection Using the 4D-NucleofectorTM LV Unit.
The LV Unit allows for closed, scalable transfection of larger cell numbers in the range of 1x107 to 1x109 cells. Transfection protocols can be established in smaller scale using the X Unit and subsequently transferred to the LV Unit without the need for re-optimization. Transferability has been tested for various cell types, including human T cells, CHO-S, HEK293-S, or K-562.
BENEFITS
• Closed system: Sterile Nucleofection of up to 109 cells
• Real scalability: Optimization in small scale
• Established protocols: Benefit from 700+ optimized cell types
• Simple handling: Minimal training needs
• 4D-NucleofectorTM LogWare: Optional operation via 21CFR part11 compliant software
APPLICATIONS
• Ex-vivo modification of human primary cells for cell therapy applications (e.g. genome editing, generation of CAR-T cells)
• Transient production of potential therapeutic proteins or antibodies for construct screening
• Generation of large numbers of transiently modified primary cells for cell-based assays
Large-Scale Transfection Using the 4D-NucleofectorTM LV Unit.
The LV Unit allows for closed, scalable transfection of larger cell numbers in the range of 1x107 to 1x109 cells. Transfection protocols can be established in smaller scale using the X Unit and subsequently transferred to the LV Unit without the need for re-optimization. Transferability has been tested for various cell types, including human T cells, CHO-S, HEK293-S, or K-562.
BENEFITS
• Closed system: Sterile Nucleofection of up to 109 cells
• Real scalability: Optimization in small scale
• Established protocols: Benefit from 700+ optimized cell types
• Simple handling: Minimal training needs
• 4D-NucleofectorTM LogWare: Optional operation via 21CFR part11 compliant software
APPLICATIONS
• Ex-vivo modification of human primary cells for cell therapy applications (e.g. genome editing, generation of CAR-T cells)
• Transient production of potential therapeutic proteins or antibodies for construct screening
• Generation of large numbers of transiently modified primary cells for cell-based assays
| CATEGORY: | INSTRUMENTS |
| SUB-CATEGORY: | LV |
| SUPPLIER: | LONZA |
| BRAND: | Nucleofector |
| DEVICE: | NUCLEOFECTOR |
Related links to "4D-Nucleofector™ LV Unit"
Available downloads: